Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Clotting Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow

NCT05087108
View directory record Official record
Conditions
Venous Thromboses, Venous Stasis
Interventions
OsciPulse system, Reference Therapy 1, Refence Therapy 2
Device
Lead sponsor
OsciFlex LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 4, 2026, 1:22 PM EDT
Not yet recruiting No phase listed Observational

TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies

NCT07692217
View directory record Official record
Conditions
Hemophilia A, Factor VIII (FVIII)
Interventions
Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 3 Interventional

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

NCT02932618
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Vonicog alfa, Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

Treatment for Blood Clots in the Veins of the Legs

NCT00001713
View directory record Official record
Conditions
Embolism, Thrombophlebitis
Interventions
Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 4, 2026, 1:22 PM EDT
Not listed Not applicable Interventional

Whole-leg Ultrasound in Pregnant Patients

NCT01319474
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Whole-leg compression ultrasound
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 4, 2026, 1:22 PM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Results available

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

NCT03103542
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant coagulation factor (rFVIIIFc)
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 4, 2026, 1:22 PM EDT
Recruiting Not applicable Interventional

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

NCT07399977
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
MSK-ACCESS, ctDNA/VTE Risk Score:
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 4, 2026, 1:22 PM EDT
Completed No phase listed Observational

A Complex Contraception Registry

NCT02219269
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 4, 2026, 1:22 PM EDT
Withdrawn No phase listed Observational

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

NCT03613402
View directory record Official record
Conditions
Venous Thromboses
Interventions
Not listed
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 4, 2026, 1:22 PM EDT
Completed No phase listed Observational

Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge

NCT03912545
View directory record Official record
Conditions
Blood Loss Massive, Trauma, Hemorrhage, Postpartum
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

NCT00989196
View directory record Official record
Conditions
Hemophilia A
Interventions
Human-cl rhFVIII, Kogenate FS
Biological
Lead sponsor
Octapharma
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 4, 2026, 1:22 PM EDT
Completed No phase listed Observational

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

NCT00776412
View directory record Official record
Conditions
Inflammation, Pathologic Processes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 4, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

NCT04081220
View directory record Official record
Conditions
Thrombocythemia, Essential
Interventions
IMG-7289
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 4, 2026, 1:22 PM EDT
Recruiting Phase 2 Interventional

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

NCT06063486
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement, Piperine Extract (Standardized), Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 4, 2026, 1:22 PM EDT
Completed No phase listed Observational

Global Impact of the COVID 19 Pandemic on Stroke Care, Cerebral Venous Thrombosis, and Subarachnoid Hemorrhage

NCT04934020
View directory record Official record
Conditions
Stroke
Interventions
Pre-pandemic stroke related metrics, Stroke related metrics during the pandemic
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
345,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 4, 2026, 1:22 PM EDT
Terminated Not applicable Interventional Results available

SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines

NCT01670188
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Pneumatic SCD - VenaFlow System (DJO Global)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

NCT03083782
View directory record Official record
Conditions
Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions
Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 4, 2026, 1:22 PM EDT
Withdrawn Phase 3 Interventional

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

NCT05104229
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Interventions
Aspirin 81Mg Ec Tab, Standard of Care
Drug
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 4, 2026, 1:22 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System

NCT02394912
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
vena cava filter implantation (LUMIFI with Crux VCF System)
Device
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Louisville, Kentucky • Orangeburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 3 Interventional

Crux Biomedical Vena Cava Filter Study - United States

NCT01120509
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Inferior Vena Cava Filter
Device
Lead sponsor
Crux Biomedical
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Orange, California • Sacramento, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 4, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 4, 2026, 1:22 PM EDT